SCHEMBL4487868

SCHEMBL4487868

Cc1[nH]c(C)c(-c2ccc(-c3ccc(Cl)cc3)nc2)c(=O)c1Br

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 2/20 0.45
BRD4 O60885 1/20 0.39
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 3/20 0.37
GAA P10253 2/20 0.36
KMT2A Q03164 2/20 0.36
MAPT P10636 2/20 0.36
MEN1 O00255 1/20 0.36
RUNX1 Q01196 1/20 0.36
CBFB Q13951 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KDM1A O60341 1/20 0.35
MAOB P27338 1/20 0.35
MAPK1 P28482 1/20 0.34
CNR2 P34972 1/20 0.34
PSD A5PKW4 2/20 0.33
GRIN2D O15399 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4490477 0.88 SLC2A1 (0.48) SLC2A1BRD4ALDH1A1KMT2AMAPT
SCHEMBL4464652 0.87 SLC2A1 (0.47) SLC2A1NPC1PSD
SCHEMBL4484308 0.87 SLC2A1 (0.48) SLC2A1GAAKMT2AMAPTMEN1
SCHEMBL4478739 0.86 SLC2A1 (0.47) SLC2A1BRD4KDM4EALDH1A1GAA
SCHEMBL4487292 0.85 SLC2A1 (0.44) SLC2A1
SCHEMBL9263799 0.84 SLC2A1 (0.59) SLC2A1BRD4KDM4EALDH1A1GAA
SCHEMBL4472787 0.84 SLC2A1 (0.58) SLC2A1KDM4EL3MBTL1KDM1AMAOB
SCHEMBL4479169 0.84 SLC2A1 (0.43) SLC2A1KDM4EALDH1A1GAAL3MBTL1
SCHEMBL9267776 0.83 SLC2A1 (0.57) SLC2A1BRD4KDM4EALDH1A1GAA
SCHEMBL4488013 0.83 SLC2A1 (0.45) SLC2A1BRD4GAAKMT2AGRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US claimed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US claimed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287461-A1 Pyridinone Derivatives Against Malaria G6PD, PNPO, PLPBP SLC2A1 2278/4885BRD4 2655/4885KDM4E 1311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.